| scholarly article | Q13442814 |
| P2093 | author name string | Robert E Click | |
| P2860 | cites work | Mycobacterium avium subspecies paratuberculosis, Crohn's disease and the Doomsday scenario | Q21092926 |
| Ulcerative colitis and Crohn's disease: is Mycobacterium avium subspecies paratuberculosis the common villain? | Q21198788 | ||
| Linking chronic infection and autoimmune diseases: Mycobacterium avium subspecies paratuberculosis, SLC11A1 polymorphisms and type-1 diabetes mellitus | Q21562352 | ||
| Mycobacteria in Crohn’s disease: how innate immune deficiency may result in chronic inflammation | Q22241484 | ||
| Adherent-invasive Escherichia coli and Crohnʼs disease | Q22242720 | ||
| Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics | Q22242875 | ||
| Long‐Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta‐Analysis of Placebo‐Controlled Trials | Q22242946 | ||
| Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum | Q22251107 | ||
| Adverse effects of biologics: a network meta-analysis and Cochrane overview | Q24234197 | ||
| Probiotics for treating acute infectious diarrhoea | Q24236704 | ||
| Probiotics for maintenance of remission in Crohn's disease | Q24244110 | ||
| Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers | Q24611219 | ||
| Bacterial evolution | Q24634394 | ||
| Small intestinal bacterial overgrowth in patients with irritable bowel syndrome | Q24674609 | ||
| Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: common neural and immune pathogenicities | Q24681823 | ||
| Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? | Q37361633 | ||
| The path to Crohn's disease: is mucosal pathology a secondary event? | Q37635078 | ||
| Innate antimicrobial immunity in inflammatory bowel diseases | Q37786633 | ||
| Probiotics and prebiotics in pediatrics | Q37813322 | ||
| Detection of Mycobacterium avium ss. Paratuberculosis in Blau Syndrome Tissues | Q38413181 | ||
| Ruminant paratuberculosis (Johne's disease): the current status and future prospects | Q40179729 | ||
| Mycobacterium avium subsp. paratuberculosis as a trigger of type-1 diabetes: destination Sardinia, or beyond? | Q40481202 | ||
| Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer | Q40538834 | ||
| Immunology: resistance to paratuberculosis | Q41128841 | ||
| Preclinical and clinical manifestations of paratuberculosis (including pathology). | Q41128846 | ||
| Treatment of clinical paratuberculosis in cattle. | Q41128868 | ||
| The pathology and pathogenesis of paratuberculosis in ruminants and other species | Q41468036 | ||
| Assessment of Dietzia subsp. C79793-74 for treatment of cattle with evidence of paratuberculosis | Q42713291 | ||
| Gut Pathogens: enteric health at the interface of changing microbiology | Q43165587 | ||
| Crohn's disease as an immunodeficiency | Q43203641 | ||
| High-dose probiotics for the treatment of active pouchitis | Q43353488 | ||
| Genetic variation and heritability of the antibody response to Mycobacterium avium subspecies paratuberculosis in Danish Holstein cows | Q43415653 | ||
| Mucosal flora in inflammatory bowel disease | Q43503928 | ||
| Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle | Q43970978 | ||
| Genetic variation of susceptibility to Mycobacterium avium subsp. paratuberculosis infection in dairy cattle | Q44734966 | ||
| Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. | Q45966647 | ||
| Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates | Q47370646 | ||
| The incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005. | Q51728016 | ||
| Probiotic yogurt for the treatment of minimal hepatic encephalopathy. | Q53134638 | ||
| Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. | Q53203839 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls. | Q54512171 | ||
| Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. | Q54700741 | ||
| Candidate gene polymorphisms (BoIFNG, TLR4, SLC11A1) as risk factors for paratuberculosis infection in cattle | Q56772017 | ||
| NOD2/CARD15 mutations in Croatian patients with Crohn??s disease: prevalence and genotype???phenotype relationship | Q57265435 | ||
| Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts | Q57697924 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease | Q60711896 | ||
| Response to infliximab is related to disease duration in paediatric Crohn's disease | Q61504346 | ||
| Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study | Q64111461 | ||
| Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease | Q73234085 | ||
| Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody | Q74582121 | ||
| Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics | Q79806151 | ||
| Successful treatment of a Crohn's disease patient infected with bacteremic Mycobacterium paratuberculosis | Q79866560 | ||
| An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease | Q80787207 | ||
| Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants | Q81224806 | ||
| Nutrition in Crohn disease | Q81386370 | ||
| Anti-mycobacterials and Crohn's disease | Q81663775 | ||
| Genetic variation of Mycobacterium avium ssp. paratuberculosis infection in US Holsteins | Q83136744 | ||
| Short communication: progression of Johne's disease curtailed by a probiotic | Q84570197 | ||
| Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine | Q24685403 | ||
| Natalizumab for active Crohn's disease | Q28201431 | ||
| Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure? | Q28211872 | ||
| Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 | ||
| Helminthic therapy: using worms to treat immune-mediated disease | Q28269580 | ||
| A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease | Q28270722 | ||
| Helminths as governors of immune-mediated inflammation | Q28289350 | ||
| Durable alteration of the colonic microbiota by the administration of donor fecal flora | Q28290783 | ||
| Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial | Q28296771 | ||
| Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial | Q29394639 | ||
| Probiotics promote gut health through stimulation of epithelial innate immunity | Q30437282 | ||
| Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. | Q33270858 | ||
| Effects of experimental immunosuppression in cattle with persistently high antibody levels to Salmonella Dublin lipopolysaccharide O-antigens | Q33293470 | ||
| Review article: the evidence base for interventions used to maintain remission in Crohn's disease | Q33301742 | ||
| A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. | Q33433931 | ||
| Probiotics in the management of colonic disorders | Q33438518 | ||
| Prevention and treatment of osteoporosis in patients with inflammatory bowel disease | Q33592715 | ||
| Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children | Q33671587 | ||
| A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial | Q33698748 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. | Q33978896 | ||
| A patented strain of Bacillus coagulans increased immune response to viral challenge | Q34016815 | ||
| Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway | Q34140466 | ||
| Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. | Q34156214 | ||
| Probiotic bacteria in the management of atopic disease: underscoring the importance of viability | Q34172898 | ||
| Probiotic therapy of intestinal inflammation and infections. | Q34554746 | ||
| Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome | Q34579610 | ||
| Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics | Q34603139 | ||
| Adalimumab safety in global clinical trials of patients with Crohn's disease | Q34607547 | ||
| Corticosteroids in Crohn's disease | Q34633102 | ||
| Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. | Q34652744 | ||
| Alterations in intestinal microbial flora and human disease | Q34718894 | ||
| Comparison of ante-mortem assays to assess progression/regression of paratuberculosis in individual dairy animals | Q34775398 | ||
| Probiotics as prevention and treatment for diarrhea | Q34912176 | ||
| Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. | Q35594940 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study | Q35597246 | ||
| Combined Streptomycin-Isoniazid-Rifampin Therapy in the Treatment of Johne's Disease in a Goat | Q35622223 | ||
| Long-term risks associated with biologic response modifiers used in rheumatic diseases. | Q35753666 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease | Q35929551 | ||
| Probiotics: an emerging therapy. | Q36005105 | ||
| Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when | Q36036286 | ||
| Review article: practical management of inflammatory bowel disease patients taking immunomodulators | Q36166363 | ||
| Inside the microbial and immune labyrinth: Gut microbes: friends or fiends? | Q36186871 | ||
| Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses. | Q36383345 | ||
| Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health | Q36394867 | ||
| Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. | Q36452334 | ||
| Probiotics in the treatment of inflammatory bowel disease. | Q36457614 | ||
| Identification of Mycobacterium avium complex in sarcoidosis. | Q36538010 | ||
| A new look at Crohn's disease: breakdown of the mucosal antibacterial defense | Q36631495 | ||
| Crohn's disease and the mycobacterioses: a review and comparison of two disease entities | Q36634773 | ||
| Safety of infliximab and other biologic agents in the inflammatory bowel diseases | Q36665637 | ||
| Safety of biologic therapy | Q36737339 | ||
| Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications | Q36793530 | ||
| Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials | Q36820897 | ||
| Treatment of Mycobacterium Paratuberculosis Infection in Ruminants | Q36868631 | ||
| Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis | Q36917257 | ||
| The mechanism of action of probiotics | Q36956063 | ||
| In utero infection of cattle with Mycobacterium avium subsp. paratuberculosis: a critical review and meta-analysis | Q36967547 | ||
| The role of probiotics in management of irritable bowel syndrome | Q36996754 | ||
| The evidence for Mycobacterium paratuberculosis in Crohn's disease | Q37016731 | ||
| Pathogenic agents in inflammatory bowel diseases | Q37214349 | ||
| What is the evidence for the use of probiotics in functional disorders? | Q37216850 | ||
| Probiotics in functional gastrointestinal disorders: what are the facts? | Q37262457 | ||
| Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? | Q37305418 | ||
| P433 | issue | 2 | |
| P921 | main subject | Mycobacterium avium avium | Q310728 |
| dexamethasone | Q422252 | ||
| probiotics | Q1816730 | ||
| P304 | page(s) | 131-143 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Virulence | Q18712614 |
| P1476 | title | Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chr | |
| P478 | volume | 2 |
| Q35214611 | A 60-day probiotic protocol with Dietzia subsp. C79793-74 prevents development of Johne's disease parameters after in utero and/or neonatal MAP infection |
| Q41905099 | A Potential 'Curative' Modality for Crohn's Disease---Modeled after Prophylaxis of Bovine Johne's Disease |
| Q42414152 | Alteration of GI symptoms in a cow with Johne disease by the dietary organosulfur, 2-mercaptoethanol |
| Q92636834 | Alternative Vaccination Routes against Paratuberculosis Modulate Local Immune Response and Interference with Tuberculosis Diagnosis in Laboratory Animal Models |
| Q46771465 | Crohn's disease therapy with Dietzia: the end of anti-inflammatory drugs |
| Q41672857 | Mechanisms of Antimicrobial Action of Cinnamon and Oregano Oils, Cinnamaldehyde, Carvacrol, 2,5-Dihydroxybenzaldehyde, and 2-Hydroxy-5-Methoxybenzaldehyde against Mycobacterium avium subsp. paratuberculosis (Map). |
| Q56768605 | Paratuberculosis (Johne's disease) in cattle and other susceptible species |
| Q38473701 | Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review |
| Q27001546 | The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials |
Search more.